Whole-Body Metabolic Tumor Volume, as Determined by 18F-FDG PET/CT, as a Prognostic Factor of Outcome for Patients With Breast Cancer Who Have Distant Metastasis-Reference-Cited by-同舟云学术

Whole-Body Metabolic Tumor Volume, as Determined by 18F-FDG PET/CT, as a Prognostic Factor of Outcome for Patients With Breast Cancer Who Have Distant Metastasis

Published:2015-10 Issue:4 Volume:205 Page:878-885
ISSN:0361-803X
Container-title:American Journal of Roentgenology
language:en
Short-container-title:American Journal of Roentgenology

Author:

Son Seung Hyun,Lee Sang-Woo,Jeong Shin Young,Song Bong-Il,Chae Yee Soo,Ahn Byeong-Cheol,Lee Jaetae

Publisher

American Roentgen Ray Society

Subject

Radiology, Nuclear Medicine and imaging,General Medicine

Reference33 articles.

1. Residual Risk of Breast Cancer Recurrence 5 Years After Adjuvant Therapy

2. Trends in Breast Cancer by Race and Ethnicity: Update 2006

3. Survival of patients with metastatic breast carcinoma

4. Prognostic factors in 1038 women with metastatic breast cancer

5. FDG-PET/CT in the staging of local/regional metastases in breast cancer

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metabolic Tumor Volume on 18-Fluorodeoxyglucose Positron Emission Tomography as a Prognostic Marker of Survival in Patients With Locally Advanced or Metastatic Neuroendocrine Neoplasms Treated With 177Lutetium-DOTA-Octreotate Peptide Receptor Radionuclide Therapy;Pancreas;2024-08

2. An Innovative Non-Linear Prediction Model for Clinical Benefit in Women with Newly Diagnosed Breast Cancer Using Baseline FDG-PET/CT and Clinical Data;Cancers;2023-11-20

3. Comparison of MRI vs. [18F]FDG PET/CT for Treatment Response Evaluation of Primary Breast Cancer after Neoadjuvant Chemotherapy: Literature Review and Future Perspectives;Journal of Clinical Medicine;2023-08-17

4. FDG PET/CT Volume-Based Quantitative Data and Survival Analysis in Breast Cancer Patients: A Systematic Review of the Literature;Current Medical Imaging Formerly Current Medical Imaging Reviews;2023-07

5. Prognostic Role of Biologically Active Volume of Disease in Patients With Metastatic Lung Adenocarcinoma;Clinical Lung Cancer;2023-05